Ningbuŋ maŋmaŋa tuhibu doro
| Ningbuŋ maŋmaŋa tuhibu doro | |
|---|---|
| Di yuli yaha | Autoimmune condition |
 | |
| Young woman with the typical "butterfly rash" found in systemic lupus erythematosus | |
| Ashibti yaɣili | Rheumatology, immunology, gastroenterology, neurology, dermatology |
| Nahingbana | Depends on the condition. Commonly low grade fever, feeling tired[1] |
| Di Piligu saha | Adulthood[1] |
| Tima | Nonsteroidal anti-inflammatory drugs, immunosuppressants, intravenous immunoglobulin[1][2] |
| Di yɔlibu biɛhigu ni | 24 million / 7% (USA)[1][3] |
Ningbuŋ maŋmaŋa tuhibu doro nyɛla doro shɛli niri ni mali ka di yirina di yi ti niŋ ka o ningbuŋ binnɛma tuhiri o ningbuŋ yaɣadin mali alaafeei.[1] Biɛhigu puuni doro ŋɔ balibu kuli paai pihinii[1] Doro ŋɔ ni tooi mali ningbuŋ yaɣili kam[4] Di nahingbana din yɔli pam n nye ningbuŋ duhibu n ti pahi wumsim[1] Di tooi zooya ka nahingbana ŋɔ kanna ka chana[1]
Baŋdiba na tooi bɛ jandi baŋ din tahiri ŋa na[4] Ningbuŋ maŋmaŋa tuhibu doro shɛŋa kamani lupus nyɛla din be zuliyanima ni, ka naan yi che shɛŋa dɔriti bee sambanni yɛla ni tahiri shɛli na[1] Dɔr' shɛŋa din be biɛhigu puuni ka nye Ningbuŋ maŋmaŋa tuhibu doro shɛŋa n nye celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, n ti pahi systemic lupus erythematosus.[1][5] Doro ŋɔ vihibaŋ ni tooi to saha shɛŋa[1]
Di tibbu dɔlila doro maa balibu n ti pahi di paai shɛm ningbuŋ maa ni[1]
Nonsteroidal anti-inflammatory drugs (NSAIDs) mini immunosuppressants n nye tila' shɛŋa bɛ ni tooi mali n tibiri ŋa.[1]Intravenous immunoglobulin gba nyɛla bɛ ni tooi zaŋ shɛli n tibi ŋa saha shɛŋa[6] Hali din ku zooi ka nahingbana niŋdi soochi la zaa yɔli, di nyɛla din bɛ tuhiri n-nyaŋdi doro ŋɔ zaasa.[1]
Paɣaba nyɛla doro ŋɔ ni tooi zooi shɛba ni n- gari dabba.[1] DI tooi zooya ka di piligiri niri daadam niŋbu bee balaga bibu saha[1]Tuuli Ningbuŋ maŋmaŋa tuhibu doro buɣisibu daa niŋla yuuni 1900 saha[7]
References
[mali niŋ | mali mi di yibu sheena n-niŋ]- 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Autoimmune diseases fact sheet. U.S. Department of Health and Human Services (16 July 2012).
- ↑ (2011) "Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases". Current Pharmaceutical Design 17 (29): 3166–75. DOI:10.2174/138161211798157540. PMID 21864262.
- ↑ Borgelt, Laura Marie (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach (in English). ASHP. p. 579. ISBN 978-1-58528-194-7. Archived from the original on 2017-09-08.
- 1 2 Borgelt, Laura Marie (2010). Women's Health Across the Lifespan: A Pharmacotherapeutic Approach (in English). ASHP. p. 579. ISBN 978-1-58528-194-7. Archived from the original on 2017-09-08.
- ↑ (February 2016) "The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets". The Lancet. Neurology 15 (2): 198–209. DOI:10.1016/S1474-4422(15)00334-8. PMID 26724103.
- ↑ (2011) "Update on intravenous immunoglobulins (IVIg) mechanisms of action and off- label use in autoimmune diseases". Current Pharmaceutical Design 17 (29): 3166–75. DOI:10.2174/138161211798157540. PMID 21864262.
- ↑ Ananthanarayan R, Paniker CK (2005). Ananthanarayan and Paniker's Textbook of Microbiology (in English). Orient Blackswan. p. 169. ISBN 9788125028086. Archived from the original on 2017-09-08.